High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro
Authors:
- Laura TorrenteLTLaura Torrente
- Gunjit MaanGMGunjit Maan
- Asma Oumkaltoum RezigARAsma Oumkaltoum Rezig
- Jean QuinnJQJean Quinn
- Angus JacksonAJAngus Jackson
- Andrea GrilliAGAndrea Grilli
- Laura CasaresLCLaura Casares
- Ying ZhangYZYing Zhang
- Evgeny KulesskiyEKEvgeny Kulesskiy
- Jani SaarelaJSJani Saarela
- Silvio BicciatoSBSilvio Bicciato
- Joanne EdwardsJEJoanne Edwards
Open Access
- 25 September 2020
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 10 (10) , 1365
Abstract
Aberrant hyperactivation of nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2) is a common event in many tumour types and associates with resistance to therapy and poor patient prognosis; however, its relevance in colorectal tumours is not well-established. Measuring the expression of surrogate genes for NRF2 activity in silico, in combination with validation in patients’ samples, we show that the NRF2 pathway is upregulated in colorectal tumours and that high levels of nuclear NRF2 correlate with a poor patient prognosis. These results highlight the need to overcome the protection provided by NRF2 and present an opportunity to selectively kill cancer cells with hyperactive NRF2. Exploiting the CRISPR/Cas9 technology, we generated colorectal cancer cell lines with hyperactive NRF2 and used them to perform a drug screen. We identified AT9283, an Aurora kinase inhibitor, for its selectivity towards killing cancer cells with hyperactive NRF2 as a consequence to either genetic or pharmacological activation. Our results show that hyperactivation of NRF2 in colorectal cancer cells might present a vulnerability that could potentially be therapeutically exploited by using the Aurora kinase inhibitor AT9283.Keywords
Funding Information
- Cancer Research UK (C52419/A22869, C20953/A18644)
- Tenovus (T18/07)
This publication has 66 references indexed in Scilit:
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Methylation of the KEAP1 gene promoter region in human colorectal cancerBMC Cancer, 2012
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesisNature, 2011
- Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanismProceedings of the National Academy of Sciences, 2011
- Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic FeaturesClinical Cancer Research, 2010
- Cysteine-based regulation of the CUL3 adaptor protein Keap1Toxicology and Applied Pharmacology, 2010
- Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancyProceedings of the National Academy of Sciences, 2008
- Novel Tricyclic Compounds Having Acetylene Groups at C-8a and Cyano Enones in Rings A and C: Highly Potent Anti-inflammatory and Cytoprotective AgentsJournal of Medicinal Chemistry, 2007
- Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung CancerPLOS Medicine, 2006
- Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsisJournal of Clinical Investigation, 2006